Journal of Cancer Research and Cellular Interventions (JCCRCI)

OLITES PUBLISHERS
A Global Approach For Research

Open Access

Short communication

Silent Signals: Understanding Epithelial Ovarian Cancer

Hapani S, Osborne R, Espina V, Grimshaw R, Herbst R, Gandara D
Division of Radiation Oncology, University of Ottawa, ON

***Corresponding Author:** Grimshaw R**,** Division of Radiation Oncology, University of Ottawa, ON

Citation: Grimshaw R (2025). Silent Signals: Understanding Epithelial Ovarian Cancer. V1(2)

Received date: September 10, 2025**: Accepted date:** September 18, 2025**: Published date:** September 22,2025

Keywords: ovulation,menache,multiple,pregances,CTscans.ovarian masses

Abstract

Epithelial ovarian cancer (EOC) is the most common and lethal form of ovarian malignancy, accounting for nearly 90% of all ovarian cancer cases. It primarily arises from the epithelial cells lining the ovary or fallopian tube. Due to vague and non-specific early symptoms—such as abdominal bloating, pelvic pain, and early satiety. EOC is often diagnosed at advanced stages, leading to poor prognosis. Risk factors include age, genetic mutations (notably BRCA1 and BRCA2), family history, and reproductive factors. Advances in diagnostic tools, including imaging and biomarkers like CA-125, along with treatment modalities such as cytoreductive surgery and platinum-based chemotherapy, have improved outcomes. Emerging targeted therapies, including PARP inhibitors, offer promising directions for personalized treatment. Early detection and awareness remain crucial to improving survival rates.

Introduction

Epithelial ovarian cancer accounts for approximately 90% of all ovarian cancer cases and represents a significant global health concern. It primarily affects postmenopausal women, although it can occur at any age. The disease is classified into several histological subtypes, including serous, mucinous, endometrioid, and clear cell carcinomas, each with distinct molecular and clinical characteristics. One of the major challenges in managing EOC is its silent progression. Early-stage disease is rarely detected due to the absence of specific symptoms and effective screening tools. Common presenting complaints—such as abdominal distension, ,pelvic discomfort, and changes in bowel habits are often mistaken for benign conditions Risk factors for EOC include increasing age, family history of ovarian or breast cancer, genetic mutations (BRCA1/BRCA2), nulliparity, and prolonged ovulation. Conversely, factors such as oral contraceptive use, pregnancy, and breastfeeding have been shown to reduce risk. Advancements in understanding the molecular biology of EOC have led to the development of targeted therapies, improving patient outcomes. However, the overall survival rate remains low due to late-stage diagnosis. Therefore, ongoing research into early detection, prevention, and personalized treatment strategies is essential to reduce the burden of this disease.

Epidemiology and Risk Factors

EOC primarily affects women over the age of 50, particularly those who are postmenopausal. Several risk factors contribute to its development, including genetic predisposition, reproductive history, and environmental influences. Mutations in the BRCA1 and BRCA2 genes significantly increase the risk, with carriers having a much higher lifetime probability of developing ovarian cancer. A family history of ovarian or breast cancer also elevates risk.

Other contributing factors include nulliparity (having no children), early menarche, late menopause, and prolonged ovulation. In contrast, protective factors include the use of oral contraceptives, multiple pregnancies, and breastfeeding, all of which reduce the number of ovulatory cycles.

Journal of Cancer Research and Cellular Interventions (JCCRCI)

Pathophysiology and Classification

EOC is not a single disease but a group of heterogeneous tumors with different histological subtypes. The major subtypes include serous, mucinous, endometrioid, and clear cell carcinomas. High-grade serous carcinoma is the most common and most aggressive form.

Molecular studies have revealed two broad categories of EOC:

- **Type I tumors:** Slow-growing and genetically stable (e.g., low-grade serous, mucinous).
- **Type II tumors:** Rapidly growing and genetically unstable (e.g., high-grade serous carcinoma).

These classifications help guide treatment strategies and prognosis

Clinical Presentation

One of the defining challenges of EOC is its "silent" nature. Early-stage disease often presents with minimal or non-specific symptoms. When symptoms do occur, they may include:

- Abdominal bloating or swelling
- Pelvic or abdominal pain
- Early satiety (feeling full quickly)
- Urinary urgency or frequency

Because these symptoms are common and often mistaken for benign conditions, diagnosis is frequently delayed until the disease has reached an advanced stage

Diagnosis

Diagnosis of EOC involves a combination of clinical evaluation, imaging, and laboratory tests. Pelvic ultrasound and CT scans are commonly used to detect ovarian masses. The tumor marker CA-125 is often elevated in EOC, although it is not specific and may be raised in other conditionsDefinitive diagnosis is made through histopathological examination following surgical biopsy or tumor removal. Staging is based on the extent of spread, ranging from Stage I (confined to ovaries) to Stage IV (distant metastasis).

Treatment

The standard treatment for EOC includes a combination of surgery and chemotherapy. Cytoreductive (debulking) surgery aims to remove as much of the tumor as possible. This is followed by platinum-based chemotherapy, typically using drugs such as carboplatin and paclitaxel

In recent years, targeted therapies have improved outcomes. PARP inhibitors, especially in patients with BRCA mutations, have shown significant promise by interfering with cancer cell DNA repair mechanisms. Anti-angiogenic agents, such as bevacizumab, are also used in certain cases to inhibit tumor blood vessel formation

Prognosis and Challenges

The prognosis of EOC largely depends on the stage at diagnosis. Early-stage disease has a relatively favorable outcome, with high survival rates. However, most patients are diagnosed at advanced stages, where the five-year survival rate drops significantly.Recurrence is common, even after initial successful treatment, making long-term management challenging. Resistance to chemotherapy is another major obstacle

Prevention and Future Directions

Preventive strategies include genetic counseling and testing for high-risk individuals. Prophylactic surgery, such as removal of the ovaries and fallopian tubes, may be recommended for women with BRCA mutations

Ongoing research focuses on improving early detection methods, understanding molecular mechanisms, and developing more effective targeted therapies. Advances in personalized medicine hold promise for better outcomes in the future

Conclusion

Epithelial ovarian cancer remains a significant health challenge due to its late presentation and high mortality rate. Despite advancements in treatment and understanding of its biology, early detection continues to be the key to improving survival. Increased awareness, genetic screening, and continued research are essential to reduce the burden of this disease and enhance patient outcomes.

References

1. Reid, B. M., et al. (2017). Epidemiology of ovarian cancer. Cancer Biology & Medicine.
2. Escudier, B, Eisen, T; Stadler, W.M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A.A.; et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 125–134.

Journal of Cancer Research and Cellular Interventions (JCCRCI)

3. Press, J.Z.; De Luca, A.; Boyd, N.; Young, S.; Troussard, A.; Ridge, Y.; Kaurah, P.; Kalloger, S.E.; Blood, K.A.; Smith, M.; et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008, 8, 17.
4. Torre, L. A., et al. (2018). Ovarian cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68(4), 284–296.
5. Krasner, C.N.; Debernardo, R.L.; Findley, M.; Penson, R.; Matulonis, U.; Atkinson, T.; Roche, M.; Seiden, M.V. Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancer. J. Clin. Oncol. 2005, 23 (16S), Abstr. 5063.
6. Gordon, A.N.; Schultes, B.C.; Gallion, H.; Edwards, R.; Whiteside, T.L.; Cermak, J.M.; Nicodemus, C.F. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol. Oncol 2004, 94, 340–351.
7. Zhu, X.; Wu, S.; Dahut, W.L.; Parikh, C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am. J. Kidney Dis. 2007, 49, 186–193.

Journal of Cancer Research and Cellular Interventions (JCCRCI)